scholarly journals Correction to: Phenotype, genotype and long-term prognosis of 40 Chinese patients with isobutyryl-CoA dehydrogenase deficiency and a review of variant spectra in ACAD8

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Junqi Feng ◽  
Chenxi Yang ◽  
Ling Zhu ◽  
Yuchen Zhang ◽  
Xiaoxu Zhao ◽  
...  
2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Junqi Feng ◽  
Chenxi Yang ◽  
Ling Zhu ◽  
Yuchen Zhang ◽  
Xiaoxu Zhao ◽  
...  

Abstract Background Isobutyryl-CoA dehydrogenase deficiency (IBDD) is a rare autosomal recessive metabolic disorder resulting from variants in ACAD8, and is poorly understood, as only dozens of cases have been reported previously. Based on a newborn screening program, we evaluated the incidence, phenotype and genotype of IBDD as well as the prognosis. Moreover, we reviewed the variant spectrum in ACAD8 associated with IBDD. Methods Forty unrelated patients with IBDD were retrospectively screened for newborns between Jan 2012 and Dec 2020. Tandem mass spectrometry (MS/MS) was used to determine the concentrations of C4-acylcarnitine, C4/C2 (acetylcarnitine), and C4/C3 (propionylcarnitine). All suspected cases were genetically tested by metabolic genes panel. Results The incidence of IBDD here was 1: 62,599. All patients presented continuously elevated C4-acylcarnitine levels with higher ratios of C4/C2 and C4/C3. Isobutyrylglycine occurred in only 8 patients. During follow-up, four patients had a transient motor delay, and two patients had growth delay. Notably, one case harbored both ACAD8 compound heterozygous variants and a KMT2A de novo variant (c.2739del, p.E914Rfs*35), with IBDD and Wiedemann–Steiner syndrome together, had exact severe global developmental delay. All patients were regularly monitored once they were diagnosed, and each patient gradually had a normal diet after 6 months of age. After 3–108 months of follow-up, most individuals were healthy except the case harboring the KMT2A variant. A total of 16 novel variants in ACAD8, c.4_5delCT, c.109C > T, c.110–2A > T, c.236G > A, c.259G > A, c.381–14G > A, c.413delA, c.473A > G, c.500delG, c.758 T > G, c.842–1G > A, c.911A > T, c.989G > A, c.1150G > C, c.1157A > G and c.1165C > T, were identified. Along with a literature review on 51 ACAD8 variants in 81 IBDD patients, we found that the most common variant was c.286G > A (27.2%), which has been observed solely in the Chinese population to date, followed by c.1000C > T (8.6%), c.1176G > T (3.7%) and c.455 T > C (3.1%). Conclusion The concentration of C4-acylcarnitine in NBS plus subsequent genetic testing is necessary for IBDD diagnosis. Both the genotypes and ACAD8 variants in IBDD are highly heterogeneous, and no significant correlations between genotype and phenotype are present here in patients with IBDD. Our IBDD cohort with detaied clinical characteristics, genotypes and long-term prognosis will be helpful for the diagnosis and management of patients with IBDD in the future.


2022 ◽  
Vol 22 (1) ◽  
Author(s):  
Peining Zhou ◽  
Zhiying Li ◽  
Li Gao ◽  
Chengli Que ◽  
Haichao Li ◽  
...  

Abstract Objective The aim of this study was to clarify the clinical characteristics and long-term outcomes of ANCA-associated vasculitis (AAV) patients with pulmonary involvement from a single Chinese cohort. Methods Newly diagnosed AAV patients with pulmonary involvement, as defined by CT, were recruited from January 2010 to June 2020. Clinical data and CT images were collected retrospectively. Baseline CTs were evaluated and re-classified into four categories: interstitial lung disease (ILD), airway involvement (AI), alveolar hemorrhage (AH), and pulmonary granuloma (PG). Results A total of 719 patients were newly diagnosed with AAV, 366 (50.9%) of whom combined with pulmonary involvement at baseline. Among the AAV cases with pulmonary involvement, 55.7% (204/366) had ILD, 16.7% (61/366) had AI alone, 14.8% (54/366) had PG, and 12.8% (47/366) had AH alone. During follow-up of a median duration of 42.0 months, 66/366 (18.0%) patients died, mainly died from infections. Survival, relapse, and infection were all significantly different based on the radiological features. Specifically, the ILD group tends to have a poor long-term prognosis, the PG group is prone to relapse, and the AI group is apt to infection. The AH group has a high risk of both early infection and relapse, thus a poor short-term prognosis. Conclusion AAV patients with diverse radiological features have different clinical characteristics and outcomes. Therefore, the intensity of immunosuppressive therapy must be carefully valued by considering the baseline CT findings among AAV patients with pulmonary involvement.


2020 ◽  
Author(s):  
Jianghua Li ◽  
Huadong Liu ◽  
Qiyun Liu ◽  
Cheng Liu ◽  
Wei Xiong ◽  
...  

Abstract Background: Heart failure (HF) is one of the leading causes of mortality and morbidity. The PARACHUTE device is designed to partition for left ventricular (LV) apical aneurysm post extensive anterior myocardial infarction. However, the long-term prognosis of the PARACHUTE device post-implantation is unclear.Methods:From November 2015 to April 2017, six subjects with New York Heart Association Class II, III and IV ischemic HF, LV ejection fraction between 15% and 40%, and LV anterior apical aneurysm were enrolled in our center. The cumulative event rates for myocardial infarction, hospitalization, and mortality were documented respectively. Further assessment of LV ejection fraction, LV end-diastolic diameter, and estimated pulmonary artery pressure were determined by echocardiography core laboratory. For quantitative data comparison, paired t‑test was employed.Results: Device implantation was successful in all six enrolled subjects, and acute device association adverse events were not observed. At 4.6 ± 1.7 years follow-up, MACEs were found in 50% patients, and the survival rate was 86.7%. We found that the LV ejection fraction was significantly elevated after deployment (46.00 ± 6.00% vs. 35.83 ± 1.47%, P=0.009). Besides, the LVEDD elevated after MI (51.17 ± 3.71 vs. 62.83 ± 3.25, P<0.001) was revealed, but the device sustained preserved LVEDD after implantation.Conclusion: The PARACHUTE device is an alternative therapy for patients with severe LV maladaptive remodeling. The procedure of PARACHUTE implantation is safe and has a potential benefit in long-term mortality reduction. However, the device seems to increase the HF ratio.Clinical Trial Registration: NCT02240940, https://clinicaltrials.gov/ct2/ show/NCT02240940


2021 ◽  
Author(s):  
Peining Zhou ◽  
Zhiying Li ◽  
Li Gao ◽  
Chengli Que ◽  
Haichao Li ◽  
...  

Abstract Objective: The aim of this study was to clarify the clinical characteristics and long-term outcomes of ANCA-associated vasculitis (AAV) patients with pulmonary involvement from a single Chinese cohort. Methods: Newly diagnosed AAV patients with pulmonary involvement, as defined by CT, were recruited from January 2010 to June 2020. Clinical data and CT images were collected retrospectively. Baseline CTs were evaluated and re-classified into four categories: interstitial lung disease (ILD), airway involvement (AI), alveolar hemorrhage (AH), and pulmonary granuloma (PG). Results: A total of 719 patients were newly diagnosed with AAV, 366 (50.9%) of whom combined with pulmonary involvement at baseline. Among the AAV cases with pulmonary involvement, 55.7% (204/366) had ILD, 16.7% (61/366) had AI alone, 14.8% (54/366) had PG, and 12.8% (47/366) had AH alone. During follow-up of a median duration of 42.0 months, 66/366 (18.0%) patients died, mainly died from infections. Survival, relapse, and infection were all significantly different based on the radiological features. Specifically, the ILD group tends to have a poor long-term prognosis, the PG group is prone to relapse, and the AI group is apt to infection. The AH group has a high risk of both early infection and relapse, thus a poor short-term prognosis.Conclusion: AAV patients with diverse radiological features have different clinical characteristics and outcomes. Therefore, the intensity of immunosuppressive therapy must be carefully valued by considering the baseline CT findings among AAV patients with pulmonary involvement.


2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Shiren Sun ◽  
Baojian Liu ◽  
Yan Wang ◽  
Ming Bai

Abstract Background and Aims Amyloid light-chain (AL) amyloidosis is a plasma cell dyscrasia characterized by the deposition of misfolded immunoglobulin light chains. The prognosis of AL patients is poor. About 70% of patients have renal involvement and one third of patients would progress to dialysis. Cyclophosphamide, thalidomide and dexamethasone (CTD) and bortezomib and dexamethasone (BDex) have shown great efficacy in patients with AL amyloidosis, especially in Chinese patients. But which option is more suitable for Chinese patients is unclear. Method We retrospectively evaluated 81 AL patients who received CTD (n = 42) or BDex (n = 39) and used Mayo stage 2012 to match 26 pairs of patients. Results In the whole cohort, the overall hematologic responses were 86% vs 91% in the CTD and BDex groups, including a complete response of 56% vs 71%, higher than most of the previously reported chemotherapies. One- and two-year overall survival (OS) was 90.2% and 81.7% with CTD regimen, and 87.6% and 82.7% with BDex regimen. After matching by Mayo stage 2012, BDex regimen showed the advantage in the depth and speed of hematologic response over CTD regimen, but there were no statistically significant differences in OS both based on the ITT analysis (P = 0.24) and 6-month landmark analysis (P = 0.48). Cardiac response was similar, while there was a trend for higher renal response in patients treated with BDex (68% vs 44%, P = 0.09). Additionally, we found that if the patients were limited to Mayo stage III or worse, BDex regimen was associated with improved survival (P = 0.009). Overall toxicities were manageable in both regimens. Severe hematologic toxicities and diarrhea should get more attention in patients treated with BDex. Conclusion This is the first comparison of BDex versus CTD in patients with AL amyloidosis. These results indicated that CTD and BDex regimens can be active and safe chemotherapy for Chinese patients, but BDex regimen is superior to CTD in achieving more rapidly and deeper clonal response, as well as in improving OS in selected patients.This conclusion is significant because we confirmed BDex regimen may be an optimal option in treating Chinese patients with AL amyloidosis. The definite advantages on long-term prognosis need to be verified in the further studies.


2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Jianghua Li ◽  
Huadong Liu ◽  
Qiyun Liu ◽  
Cheng Liu ◽  
Wei Xiong ◽  
...  

Abstract Background Heart failure (HF) is one of the leading causes of mortality and morbidity. The PARACHUTE device is designed to partition for left ventricular (LV) apical aneurysm post extensive anterior myocardial infarction (MI). However, the long-term prognosis of the PARACHUTE device post-implantation is unclear. Methods From November 2015 to April 2017, six subjects with New York Heart Association Classes II, III and IV ischemic HF, LV ejection fraction between (LVEF) 15 and 40%; and LV anterior apical aneurysm were enrolled in our center. The cumulative event rates for MI, hospitalization, and mortality were documented. Further assessment of LVEF, LV end-diastolic diameter (LVEDD), and estimated pulmonary artery pressure were determined by echocardiography core laboratory. For quantitative data comparison, paired t-test was employed. Results Device implantation was successful in all six enrolled subjects, and acute device association adverse events were not observed. At 4.6 ± 1.7 years follow-up, major adverse cardiac events (MACEs) were found in 50% patients, and the survival rate was 86.7%. We observed that the LVEF was significantly elevated after deployment (46.00 ± 6.00% vs. 35.83 ± 1.47%, P = 0.009). Besides, the LVEDD elevated after MI (51.17 ± 3.71 vs. 62.83 ± 3.25, P < 0.001) was revealed, but the device sustained preserved LVEDD after implantation. Conclusion The PARACHUTE device is an alternative therapy for patients with severe LV maladaptive remodeling. However, the device seems to increase the HF ratio. Trial registration NCT02240940


Sign in / Sign up

Export Citation Format

Share Document